GlobeNewswire

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
13/11/2025
Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and [...]
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
13/11/2025
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13/11/2025
Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING [...]
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
13/11/2025
Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased Cash Balance of $ [...]
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
13/11/2025
KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. ( CSE: MOOD | PINK: DOSEF | FSE: VU70 ) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is [...]
IMU Biosciences announces formation of Scientific Advisory Board
13/11/2025
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics London, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company [...]
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
13/11/2025
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment All six patients responded positively to the combination Overall response data [...]
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
13/11/2025
$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and [...]
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
13/11/2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum